<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035186</url>
  </required_header>
  <id_info>
    <org_study_id>0305083</org_study_id>
    <nct_id>NCT05035186</nct_id>
  </id_info>
  <brief_title>Efficacy of Clarithromycin and Flouroquinolones Based Regimens in H.Pylori Eradication in Covid-19 Era</brief_title>
  <official_title>Efficacy of Clarithromycin and Flouroquinolones Based Regimens in H.Pylori Eradication in Covid-19 Era: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Era of COVID-19 and the related panic lead to widely spread antibiotics misuse especially for&#xD;
      azithromycin. Cross sensitivity between azithromycin and clarithromycin can impact success&#xD;
      rates of H. pylori treatment regimens.(1) Here we aim to explore this point in Egyptian&#xD;
      patients.&#xD;
&#xD;
      Sample size Supposing the cure rate of clarithromycin-based regimen to levofloxacin based&#xD;
      regimen is 69% versus 84.5% respectively. Using Medcalc, the minimal required sample size is&#xD;
      116 patients for each arm (type 1 error= 5%, type II error=20%). Each arm increased by 10% to&#xD;
      compensate for drop-out. The sample size will be 135 for each arm.&#xD;
&#xD;
      Study Arms:&#xD;
&#xD;
        -  Arm 1: The first group will receive (amoxicillin 1g/12 hrs, Clarithromycin 500 mg/12hrs,&#xD;
           esomeprazole 40mg/12hrs)&#xD;
&#xD;
        -  Arm 2: The second group will receive (esomeprazole 40 mg/12hrs, levofloxacin 500 mg/24&#xD;
           hrs, and amoxicillin 1gm/12 hrs).&#xD;
&#xD;
        -  To confirm patient compliance, we will ask patients to bring their remaining medication&#xD;
           and counted the rest of their pills. Patients with a compliance of &lt;80% will be excluded&#xD;
           from the study per protocol (PP) analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2021</start_date>
  <completion_date type="Anticipated">November 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H. pylori eradication rates</measure>
    <time_frame>6 weeks from end of treatment and at least 2 weeks with no administration of PPIs</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clarithromycin based</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levofloxacin based</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Anti-H. pylori regimens</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Clarithromycin</other_name>
    <other_name>Levofloxacin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Patients aged 18-64 years old with newly diagnosed positive H. pylori antigen in&#xD;
             stools, urea breath test or H. pylori detected on endoscopy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Women who were pregnant or lactating, patients previously treated with H. pylori&#xD;
             eradication therapy, patients who previously underwent gastric surgery, patients with&#xD;
             malignant neoplasms, and patients with other severe concomitant diseases like renal,&#xD;
             hepatic impairement, heart failure NYHA class II or more, hypoalbuminemia will be&#xD;
             excluded.&#xD;
&#xD;
               -  Known allergy to antibiotics.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Kamal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Kamal, MD, PhD</last_name>
    <email>Ahmed.kamal@alexmed.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Kamal</last_name>
    <phone>01279734654</phone>
    <email>Ahmed.kamal.med@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alexandria University.</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Kamal</last_name>
      <phone>01279734654</phone>
      <email>Ahmed.Kamal@alexmed.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Ahmed Kamal</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

